August 2012 Newsletter

August 30, 2012:

US Refractive Surgery Weaker than Expected in Q2-2012, Reflecting Fragile Economy

Performance in the US refractive surgery market was mixed in Q2-2012, with some surgeons reporting declines in volume while others saw healthy growth.

August 30, 2012:

US IOL Procedures Climb 3.4 Percent in Q2-2012

US IOL procedures remained roughly on pace with long-term trends, according to cataract surgeons responding to our recent survey.

August 30, 2012:

FDA Panel Recommends Approval for Thrombogenics’ Jetrea in Treatment of Symptomatic VMA

FDA advisory committee voted unanimously that the benefits of administering ocriplasmin for symptomatic VMA outweigh risks.

August 30, 2012:

Lucentis Gains FDA Clearance for DME in 0.3 mg Dose

The drug is the first to gain the FDA’s approval for this complication of diabetes.

August 30, 2012:

Upcoming ESCRS and EURETINA Meetings Promise New Technology Updates

As many as 6,000 doctors are expected in Italy for the ESCRS meeting, which some consider the most important gathering of the year.

August 30, 2012:

Iluvien is Dealt New Blow by UK Cost Watchdog

The drug fails to win the backing of the agency that oversees health care costs in the UK.

August 30, 2012:

Healthy Growth Rate Forecast for the Single-Use Ophthalmic Surgical Device Market

Market Scope expects the global ophthalmic single-use surgical product market to generate $2.3 billion in sales in 2012.

August 30, 2012:

Market Scope Expands Glaucoma Coverage as Industry Picks Up Momentum

August 30, 2012:

August 2012 News Briefs

Social media